PT3515465T - Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r - Google Patents
Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4rInfo
- Publication number
- PT3515465T PT3515465T PT177771458T PT17777145T PT3515465T PT 3515465 T PT3515465 T PT 3515465T PT 177771458 T PT177771458 T PT 177771458T PT 17777145 T PT17777145 T PT 17777145T PT 3515465 T PT3515465 T PT 3515465T
- Authority
- PT
- Portugal
- Prior art keywords
- administering
- inhibitor
- methods
- atopic dermatitis
- treating severe
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 208000037851 severe atopic dermatitis Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/247—IL-4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17306081 | 2017-08-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3515465T true PT3515465T (pt) | 2024-03-04 |
Family
ID=59772561
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT177771458T PT3515465T (pt) | 2017-08-18 | 2017-09-21 | Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r |
Country Status (4)
Country | Link |
---|---|
US (2) | US10485844B2 (pt) |
MA (1) | MA46269B1 (pt) |
PT (1) | PT3515465T (pt) |
WO (1) | WO2018057776A1 (pt) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201500889TA (en) | 2012-08-21 | 2015-03-30 | Sanofi Sa | Methods for treating or preventing asthma by administering an il-4r antagonist |
TWI633891B (zh) | 2013-06-04 | 2018-09-01 | 再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法 |
KR20240128110A (ko) | 2014-02-28 | 2024-08-23 | 리제너론 파아마슈티컬스, 인크. | Il-4r 길항제의 투여에 의한 피부 감염의 치료 방법 |
WO2016077675A1 (en) | 2014-11-14 | 2016-05-19 | Sanofi Biotechnology | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist |
CN113372446A (zh) | 2016-06-08 | 2021-09-10 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
MA46098A (fr) | 2016-09-01 | 2019-07-10 | Regeneron Pharma | Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r |
WO2018057776A1 (en) | 2016-09-22 | 2018-03-29 | Regeneron Pharmaceuticals, Inc. | Methods for treating severe atopic dermatitis by administering an il-4r inhibitor |
US11053309B2 (en) | 2017-08-04 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating active eosinophilic esophagitis |
CA3079946A1 (en) | 2017-10-30 | 2019-05-09 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4r antagonist |
SG11202009371WA (en) * | 2018-05-13 | 2020-10-29 | Regeneron Pharma | Methods for treating atopic dermatitis by administering an il-4r inhibitor |
US11312778B2 (en) | 2018-11-21 | 2022-04-26 | Brian C. Machler | Method for treating allergic contact dermatitis |
CN111518211B (zh) | 2018-12-25 | 2022-06-21 | 江苏荃信生物医药股份有限公司 | 抗人白介素4受体α单克隆抗体的制药用途 |
WO2020191346A1 (en) | 2019-03-21 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
CA3147113A1 (en) | 2019-08-05 | 2021-02-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r antagonist |
SG11202113312VA (en) | 2019-08-05 | 2021-12-30 | Regeneron Pharma | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist |
CN115461818A (zh) | 2019-12-09 | 2022-12-09 | 赛诺菲生物技术公司 | 治疗数字鉴定的il-4/il-13相关障碍的方法 |
EP3992974A1 (en) | 2020-11-02 | 2022-05-04 | Sanofi Biotechnology | Methods for treating digitally-identified il-4/il-13 related disorders |
JP2023520676A (ja) | 2020-03-27 | 2023-05-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Il-4rアンタゴニストを投与することによりアトピー性皮膚炎を処置するための方法 |
JP2024532263A (ja) | 2021-08-23 | 2024-09-05 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Il-4rアンタゴニストを投与することによってアトピー性皮膚炎を治療する方法 |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8808015D0 (en) | 1988-04-06 | 1988-05-05 | Ritter M A | Chemical compounds |
AU643427B2 (en) | 1988-10-31 | 1993-11-18 | Immunex Corporation | Interleukin-4 receptors |
BR9205967A (pt) | 1991-05-03 | 1994-07-26 | Seragen Inc | Moléculas marcadas com receptor de interleucina tratamento de artrite inflamatória |
JP3315427B2 (ja) | 1992-03-05 | 2002-08-19 | 大日本除蟲菊株式会社 | 皮膚炎治療剤 |
US5714146A (en) | 1992-08-26 | 1998-02-03 | Board Of Regents Of The University Of Washington | IL-4 bone therapy |
EP0604693A1 (en) | 1992-12-29 | 1994-07-06 | Schering-Plough | Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same |
RU2162711C2 (ru) | 1993-09-07 | 2001-02-10 | Смитклайн Бичам Корпорейшн | Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4 |
WO2000016804A1 (en) | 1998-09-18 | 2000-03-30 | Dynavax Technologies Corporation | METHODS OF TREATING IgE-ASSOCIATED DISORDERS AND COMPOSITIONS FOR USE THEREIN |
EP2292665B1 (en) | 2000-05-26 | 2015-07-08 | Immunex Corporation | Use of interleukin-4 antibodies and compositions thereof |
US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
AU2001267917A1 (en) | 2000-07-26 | 2002-02-05 | Kenjirou Tsuchida | Antipruritic compositions and compositions promoting wound healing |
US20030103938A1 (en) | 2001-05-09 | 2003-06-05 | Alk-Abello A/S | Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio |
US20050031609A1 (en) | 2001-05-11 | 2005-02-10 | Thomas Hultsch | Compositions for use in treating ige-associated disorders |
DK1450855T3 (da) | 2001-05-23 | 2010-01-11 | Duotol Ab | Undertrykkelse af allergiske reaktioner ved hjælp af transdermal indgivelse af allergener i forbindelse med eller konjugeret til toxin-underenheder eller fragmenter deraf |
EP2990394A1 (en) | 2001-11-30 | 2016-03-02 | Biogen MA Inc. | Antibodies against monocyte chemotactic proteins |
SI1527100T1 (sl) | 2002-03-29 | 2009-12-31 | Schering Corp | Humana monoklonska protitelesa proti interlevkinu-5 in postopki in sestavki, ki jih obsegajo |
MXPA05005528A (es) | 2002-11-26 | 2006-04-05 | Alk Abello As | Producto farmaceutico de alergeno. |
PT2000481E (pt) | 2003-02-01 | 2016-06-17 | Tanox Inc | Anticorpos anti-ige humana de alta afinidade |
US7923209B2 (en) | 2003-03-14 | 2011-04-12 | Anergis, S.A. | Allergen peptide fragments and use thereof |
ATE548388T1 (de) | 2003-11-07 | 2012-03-15 | Immunex Corp | An den interleukin-4-rezeptor bindende antikörper |
US7884054B2 (en) | 2003-12-22 | 2011-02-08 | Amgen Inc. | Methods for identifying functional antibodies |
ATE395358T1 (de) | 2004-02-27 | 2008-05-15 | Regeneron Pharma | Il-4/il-13-spezifische polypetide und deren therapeutische verwendung |
US20090098142A1 (en) | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
JP5234445B2 (ja) | 2004-10-05 | 2013-07-10 | 源一郎 杣 | 薬剤 |
WO2006083390A2 (en) | 2004-12-07 | 2006-08-10 | Children's Hospital Medical Center | Eotaxin-3 in eosinophilic esophagitis |
TWI306862B (en) | 2005-01-03 | 2009-03-01 | Hoffmann La Roche | Antibodies against il-13 receptor alpha 1 and uses thereof |
US8324192B2 (en) | 2005-11-12 | 2012-12-04 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
US8679545B2 (en) | 2005-11-12 | 2014-03-25 | The Regents Of The University Of California | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
JP4221018B2 (ja) | 2006-08-31 | 2009-02-12 | トヨタ自動車株式会社 | 頭部保護エアバッグ装置 |
US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
MX2009003393A (es) | 2006-10-02 | 2009-05-11 | Regeneron Pharma | Anticuerpos humanos de alta afinidad para el receptor de il-4 humano. |
JP5723594B2 (ja) | 2007-03-22 | 2015-05-27 | ジェネンテック, インコーポレイテッド | アポトーシス性抗IgE抗体 |
EP2022507A1 (en) | 2007-08-07 | 2009-02-11 | Universität Hamburg | Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy |
WO2009061819A1 (en) | 2007-11-05 | 2009-05-14 | The Regents Of The University Of Colorado | Minimally-invasive measurement of esophageal inflammation |
US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
DE202008006598U1 (de) | 2008-04-11 | 2008-10-02 | Alk-Abelló A/S | Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung |
US20090264392A1 (en) | 2008-04-21 | 2009-10-22 | Meritage Pharma, Inc. | Treating eosinophilic esophagitis |
EP2376656A4 (en) | 2008-12-01 | 2012-05-16 | Cincinnati Children S Hospital Medical Ct | METHODS FOR DETERMINING THE EFFECTIVENESS OF GLUCOCORTICOID TREATMENT OF SOSHOPHILIC OOPHAGITIS |
US20120088814A1 (en) | 2009-03-31 | 2012-04-12 | Isis Pharmaceuticals, Inc. | Methods of modulating an immune response to a viral infection |
US8497528B2 (en) | 2010-05-06 | 2013-07-30 | Taiwan Semiconductor Manufacturing Company, Ltd. | Method for fabricating a strained structure |
US20110037054A1 (en) | 2009-08-17 | 2011-02-17 | Chan-Long Shieh | Amoled with cascaded oled structures |
WO2011026966A2 (en) | 2009-09-07 | 2011-03-10 | Dbv Technologies | Method of treating eosinophilic esophagitis |
US8075895B2 (en) | 2009-09-22 | 2011-12-13 | Janssen Pharmaceutica N.V. | Identification of antigenic peptides from multiple myeloma cells |
US8993347B2 (en) | 2009-12-17 | 2015-03-31 | Cornell University | Methods for detecting antibodies in mucosal samples and device for sampling mucosal material |
ES2894936T3 (es) | 2010-06-24 | 2022-02-16 | Viropharma Biologics Llc | Métodos de tratamiento para la inflamación del esófago |
PL2624865T3 (pl) | 2010-10-06 | 2018-11-30 | Regeneron Pharmaceuticals, Inc. | Stabilizowane preparaty zawierające przeciwciała przeciwko receptorowi interleukiny-4 (IL-4R) |
RU2453303C1 (ru) | 2010-12-23 | 2012-06-20 | Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") | Фармацевтическая композиция для лечения атопического дерматита |
CA2824043A1 (en) | 2011-01-06 | 2012-07-12 | Marc E. Rothenberg | Esophageal cytokine expression profiles in eosinophilic esophagitis |
US20130052190A1 (en) | 2011-02-22 | 2013-02-28 | Oxagen Limited | CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions |
WO2012177945A2 (en) | 2011-06-21 | 2012-12-27 | Children's Hospital Medical Center | Diagnostic methods for eosinophilic esophagitis |
CN103974706A (zh) | 2011-10-06 | 2014-08-06 | N·V·努特里奇亚 | 嗜酸细胞性食管炎的治疗 |
KR20140113667A (ko) | 2011-12-16 | 2014-09-24 | 아토픽스 테라퓨릭스 리미티드 | 호산구성 식도염의 치료를 위한 crth2 길항제 및 양성자 펌프 저해제의 조합 |
SG11201404486QA (en) | 2012-01-31 | 2014-11-27 | Genentech Inc | Anti-ig-e m1' antibodies and methods using same |
WO2013155010A1 (en) | 2012-04-09 | 2013-10-17 | Children's Hospital Medical Center | Non-invasive biomarkers for eosinophilic esophagitis |
SG11201500889TA (en) | 2012-08-21 | 2015-03-30 | Sanofi Sa | Methods for treating or preventing asthma by administering an il-4r antagonist |
WO2014039461A1 (en) | 2012-09-07 | 2014-03-13 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r antagonist |
WO2014059178A1 (en) | 2012-10-10 | 2014-04-17 | Rhode Island Hospital | Differential expression of novel protein markers for the diagnosis and treatment of eosinophilic esophagitis |
TWI633891B (zh) | 2013-06-04 | 2018-09-01 | 再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
KR20230066127A (ko) | 2013-06-21 | 2023-05-12 | 사노피 바이오테크놀로지 | Il-4r 길항제를 투여함에 의한 비용종증의 치료 방법 |
TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法 |
CN106232140A (zh) | 2014-02-21 | 2016-12-14 | 赛诺菲生物技术公司 | 通过施用il‑4r拮抗剂治疗或预防哮喘的方法 |
KR20240128110A (ko) | 2014-02-28 | 2024-08-23 | 리제너론 파아마슈티컬스, 인크. | Il-4r 길항제의 투여에 의한 피부 감염의 치료 방법 |
WO2016077675A1 (en) * | 2014-11-14 | 2016-05-19 | Sanofi Biotechnology | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist |
JP2019505554A (ja) | 2016-02-19 | 2019-02-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Il−4rアンタゴニストを投与することによるワクチンの有効性を増強する方法 |
MA46098A (fr) | 2016-09-01 | 2019-07-10 | Regeneron Pharma | Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r |
WO2018057776A1 (en) | 2016-09-22 | 2018-03-29 | Regeneron Pharmaceuticals, Inc. | Methods for treating severe atopic dermatitis by administering an il-4r inhibitor |
KR20240063204A (ko) | 2017-02-17 | 2024-05-10 | 프레드 허친슨 캔서 센터 | Bcma 관련 암 및 자가면역 장애의 치료를 위한 조합 요법 |
WO2018201051A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
CA3079946A1 (en) | 2017-10-30 | 2019-05-09 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4r antagonist |
SG11202009371WA (en) | 2018-05-13 | 2020-10-29 | Regeneron Pharma | Methods for treating atopic dermatitis by administering an il-4r inhibitor |
WO2020191346A1 (en) | 2019-03-21 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
CA3147113A1 (en) | 2019-08-05 | 2021-02-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r antagonist |
SG11202113312VA (en) | 2019-08-05 | 2021-12-30 | Regeneron Pharma | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist |
-
2017
- 2017-09-21 WO PCT/US2017/052772 patent/WO2018057776A1/en unknown
- 2017-09-21 US US15/711,815 patent/US10485844B2/en active Active
- 2017-09-21 MA MA46269A patent/MA46269B1/fr unknown
- 2017-09-21 PT PT177771458T patent/PT3515465T/pt unknown
-
2019
- 2019-07-16 US US16/513,285 patent/US11167004B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US11167004B2 (en) | 2021-11-09 |
WO2018057776A1 (en) | 2018-03-29 |
MA46269A (fr) | 2019-07-31 |
US20180078603A1 (en) | 2018-03-22 |
US10485844B2 (en) | 2019-11-26 |
MA46269B1 (fr) | 2024-05-31 |
US20200246416A1 (en) | 2020-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT3515465T (pt) | Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r | |
SG11202009371WA (en) | Methods for treating atopic dermatitis by administering an il-4r inhibitor | |
IL285201A (en) | EZH2 inhibitors for the treatment of lymphoma | |
IL256056A (en) | ezh2 inhibitors for the treatment of lymphoma | |
IL265516A (en) | Methods for treating severe allergic dermatitis by administering an il-4r inhibitor | |
IL289930A (en) | Methods for treating atopic dermatitis using an IL-4R antagonist | |
HK1249469A1 (zh) | 用RORγ抑制劑治療癌症的方法 | |
IL279308A (en) | Methods for the treatment of heptidine-mediated disorders | |
IL281318A (en) | A method for treating medulloblastoma with an EZH2 inhibitor | |
EP3134120A4 (en) | Compositions and methods for treating cytokine-related disorders | |
EP3126004A4 (en) | Methods and compositions for treating inflammatory disorders | |
EP3368042A4 (en) | METHOD OF TREATING EPILEPSY | |
EP3226972A4 (en) | Methods and compositions for treating migraine and conditions associated with pain | |
ZA201600048B (en) | Method for treating internal arcs | |
EP3154546A4 (en) | Methods for treating pruritus | |
EP3142699A4 (en) | Compositions and methods for treating metabolic disorders | |
EP3262065A4 (en) | Methods and compositions for treating dystroglycanopathy disorders | |
EP3277857A4 (en) | Carburization of steel components | |
ZA201903005B (en) | Methods and compositions for treating atopic dermatitis | |
EP3250218A4 (en) | Methods for treating obesity | |
EP3139911A4 (en) | Method of treating advanced non-alcoholic steatohepatitis | |
HK1257072A1 (zh) | 治療多發性硬化的方法 | |
EP3246432A4 (en) | Method for treating parts | |
EP3659615A4 (en) | PHARMACEUTICAL PREPARATION FOR TREATING ATOPIC DERMATITIS | |
EP3368158A4 (en) | THIRD SPACE PROCESSING METHOD |